Literature DB >> 11291106

Plasma and urinary endothelin-1 in focal segmental glomerulosclerosis.

H C Chen1, J Y Guh, J M Chang, J C Tsai, S J Hwang, Y H Lai.   

Abstract

The kidney is an important site of endothelin-1 (ET-1) production and is particularly susceptible to ET-1 action. Infusion of ET-1 in rats induces both functional and morphological alterations in the kidneys. Increased plasma level of ET-1 has been reported in patients with chronic renal failure. However, there are still no reports on the plasma and urinary ET-1 levels in patients with focal segmental glomerulosclerosis (FSGS). In the present study, we have measured the plasma concentration and urinary excretion rate of ET-1 in 15 patients with nephrotic syndrome due to FSGS, and observed the serial changes of plasma and urinary ET-1 in nephrotic rats with FSGS, induced by repeated injection with puromycin aminonucleoside (PAN). ET-1 was measured with radioimmunoassay. The results showed that plasma ET-1 concentration in FSGS patients was significantly higher than in normal controls (P < 0.05), and that urinary ET-1 excretion rate was also significantly higher in FSGS patients than in normal controls (P < 0.01). In FSGS patients, the plasma and urinary ET-1 was significantly correlated (P < 0.05), and the urinary ET-1 excretion rate was significantly correlated with the amount of proteinuria (P < 0.05) and the glomerular sclerosing score (P < 0.01). In the ten rats with PAN-induced FSGS, serial examination showed a significant increase in plasma ET-1 after 8 weeks of injections, while the urinary ET-1 excretion rate showed a biphasic increase that showed a peak after 4 to 6 weeks. The same changes in plasma and urinary ET-1 levels were not observed in control rats injected with normal saline at the same frequency. Our results suggest that ET-1 may be involved in the pathogenesis of FSGS in both humans and rats.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11291106      PMCID: PMC6807797          DOI: 10.1002/jcla.2

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  21 in total

1.  Angiotensin II and endothelin in chronic glomerulonephritis.

Authors:  D E Kohan
Journal:  Kidney Int       Date:  1998-08       Impact factor: 10.612

2.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

Review 3.  Endothelins in the kidney: physiology and pathophysiology.

Authors:  D E Kohan
Journal:  Am J Kidney Dis       Date:  1993-10       Impact factor: 8.860

4.  Time course and localization of endothelin-1 gene expression in a model of renal disease progression.

Authors:  I Bruzzi; D Corna; C Zoja; S Orisio; E L Schiffrin; D Cavallotti; G Remuzzi; A Benigni
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

Review 5.  Endothelins in the normal and diseased kidney.

Authors:  D E Kohan
Journal:  Am J Kidney Dis       Date:  1997-01       Impact factor: 8.860

6.  Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats.

Authors:  E Brochu; S Lacasse; C Moreau; M Lebel; I Kingma; J H Grose; R Larivière
Journal:  Nephrol Dial Transplant       Date:  1999-08       Impact factor: 5.992

7.  Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

Authors:  B Hocher; C Thöne-Reineke; P Rohmeiss; F Schmager; T Slowinski; V Burst; F Siegmund; T Quertermous; C Bauer; H H Neumayer; W D Schleuning; F Theuring
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

8.  Vascular and glomerular expression of endothelin-1 in normal human kidney.

Authors:  W H Herman; S N Emancipator; R L Rhoten; M S Simonson
Journal:  Am J Physiol       Date:  1998-07

9.  Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis.

Authors:  J Grond; J Koudstaal; J D Elema
Journal:  Kidney Int       Date:  1985-02       Impact factor: 10.612

10.  Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth.

Authors:  D Gómez-Garre; M Ruiz-Ortega; M Ortego; R Largo; M J López-Armada; J J Plaza; E González; J Egido
Journal:  Hypertension       Date:  1996-04       Impact factor: 10.190

View more
  4 in total

1.  Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis.

Authors:  Ilse Daehn; Gabriella Casalena; Taoran Zhang; Shaolin Shi; Franz Fenninger; Nicholas Barasch; Liping Yu; Vivette D'Agati; Detlef Schlondorff; Wilhelm Kriz; Borje Haraldsson; Erwin P Bottinger
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

Review 2.  Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition.

Authors:  Ariela Benigni; Simona Buelli; Donald E Kohan
Journal:  Pediatr Nephrol       Date:  2020-03-17       Impact factor: 3.714

3.  Endothelial Endothelin Receptor A Expression Is Associated With Podocyte Injury and Oxidative Stress in Patients With Focal Segmental Glomerulosclerosis.

Authors:  Nina A van de Lest; Aimée E Bakker; Kyra L Dijkstra; Malu Zandbergen; Sharon A C Heemskerk; Ron Wolterbeek; Jan A Bruijn; Marion Scharpfenecker
Journal:  Kidney Int Rep       Date:  2021-04-22

Review 4.  The glomerular filtration barrier: a structural target for novel kidney therapies.

Authors:  Ilse S Daehn; Jeremy S Duffield
Journal:  Nat Rev Drug Discov       Date:  2021-07-14       Impact factor: 84.694

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.